2. Cardiovascular Disease

Cardiovascular Disease

Cardiovascular Disease

Related Products

PDF 32.36 MB

Cardiovascular diseases (CVDs) are the leading causes of death and disability worldwide. CVDs include diseases of the heart, vascular diseases of the brain and diseases of blood vessels. Caused by atherosclerosis, coronary heart disease and cerebrovascular disease are the most common forms of CVDs. Other less common forms of CVDs include rheumatic heart disease and congenital heart disease. A large percentage of CVDs is preventable through the reduction of behavioral risk factors such as tobacco use, physical inactivity and unhealthy diet. Dietary sodium reduction can alleviate the long-term risk of cardiovascular disease events. Statin therapy is an effective intervention in both the primary and secondary preventions of CVDs in those who are at high risk.

Cat. No. Product Name CAS No. Purity Chemical Structure
  • HY-176805
    TGP-377 2665700-67-2 98%
    TGP-377 is a potent miR-377 inhibitor that specifically and effectively enhances VEGFA expression by targeting the non-coding microRNA that regulates VEGFA expression.
    TGP-377
  • HY-176817
    GPR109 receptor agonist-3 944559-31-3
    GPR109 receptor agonist-3 is an orally active GPR109 receptor agonist, with an IC50 of 310 nM. GPR109 receptor agonist-3 retains the antioxidation and cytoprotection of Lipoic acid (HY-18733). GPR109 receptor agonist-3 reduces total cholesterol (TC), triglyceride (TG), low-density lipoprotein cholesterol (LDL-C) and increases high-density lipoprotein cholesterol (HDL-C) in high-fat diet-fed rats. GPR109 receptor agonist-3 can be used for the study of atherosclerosis.
    GPR109 receptor agonist-3
  • HY-176840
    Carboxylesterase-IN-4 819869-10-8
    Carboxylesterase-IN-4 (compound 3e) is a potent carboxylesterase inhibitor with an IC50 of 1.58 nM. Carboxylesterase-IN-4 can be used in the study of cholesterolemia.
    Carboxylesterase-IN-4
  • HY-176841
    Carboxylesterase-IN-5 648894-93-3
    Carboxylesterase-IN-5 (Compound 2e) is an irreversible and competitive Carboxylesterase (CES) inhibitor with an IC50 of 21.7  nM for porcine liver CES. Carboxylesterase-IN-5 can be used for hypocholesterolemia research.
    Carboxylesterase-IN-5
  • HY-176914
    Myosin-IN-3 3103487-72-2 98%
    Myosin-IN-3 is a pyrimidine ketone derivative. Myosin-IN-3 exhibits significant anti ferroptotic activity (IC50 = 3.11 μM) while possessing myosin (IC50 = 3.09 μM) inhibitory activity and antioxidant activity (DPPH EC50 = 23.17 μM; MDA EC50 = 55.34 μM). Myosin-IN-3 can be used for research on heart conditions such as hypertrophic cardiomyopathy.
    Myosin-IN-3
  • HY-177062
    NPRA agonist-11 3055143-61-5 98%
    NPRA agonist-11 (Example 161) is an NPRA (NPR1) agonist, with AC50 values of 1.681 μM and 0.989 μM for humans and monkeys, respectively. NPRA agonist-11 can be used in the research of cardiovascular diseases and other disorders.
    NPRA agonist-11
  • HY-177128
    Sebrinoflast 2919854-67-2
    Sebrinoflast (Compound 5) is a NLRP3 inhibitor with an IC50 ≤1  μM for hNLRP3. Sebrinoflast can be used for inflammatory and cardiovascular diseases including NASH and atherosclerosis and neurological diseases like Alzheimer's disease research.
    Sebrinoflast
  • HY-177148
    G256 134867-97-3
    G256 (Compound 1) is an amidinohydrazone. G256 can also be considered as a Schiff’s base of aminoguanidine. G256 exhibits antiarrhythmic activity. G256 is the reduced form of NOH-G256 by microsomal enzyme preparation from rabbit and rat liver homogenates in the presence of NADPH and NADH.
    G256
  • HY-177204
    DSPE-PEG2000-WLSEAGPVVTVRALRGTGSW
    DSPE-PEG2000-WLSEAGPVVTVRALRGTGSW is a PEG compound which composed of DSPE and a cardiomyocyte specific peptide (WLSEAGPVVTVRALRGTGSW) (HY-P3436). DSPE-PEG2000-WLSEAGPVVTVRALRGTGSW can be used for drug delivery.
    DSPE-PEG2000-WLSEAGPVVTVRALRGTGSW
  • HY-177205
    DSPE-PEG2000-CRPPR
    DSPE-PEG2000-CRPPR is a PEG compound which composed of DSPE and a Heart-homing peptide (CRPPR) (HY-P10641). DSPE-PEG2000-CGKRK can be used for drug delivery.
    DSPE-PEG2000-CRPPR
  • HY-177291
    LAB687 256397-11-2
    LAB687 (Compound 2a) is a Microsomal triglyceride transfer protein (MTP) inhibitor with an IC50 of 0.9  nM for the secretion of apoB from HepG2 cells. LAB687 is also a Smoothened (Smo) antagonist with IC50s of 2.48 and 3.42 μM for mouse and human Smo receptor, respectively. LAB687 can lower the level of triglycerides and LDL cholesterol and inhibits the Hedgehog signaling pathway.
    LAB687
  • HY-177292
    Renin-IN-3 911113-39-8
    Renin-IN-3 (Example 10) is a Renin inhibitor. Renin-IN-3 can be sued for hypertension research.
    Renin-IN-3
  • HY-177326
    Ciprokiren 143631-62-3
    Ciprokiren (Ro 44-9375) is a Renin inhibitor with IC50s of 0.07 and 0.65 nM for hRenin in buffer and plasma, respectively. Ciprokiren be applied transdermally with similar hemodynamic effects without decrease of plasma renin activity or plasma immunoreactive angiotensin II. Ciprokiren has antihypertensive efficacy and can be used for hypertension research.
    Ciprokiren
  • HY-177329
    U-80125 123300-09-4 98%
    U80215, a dansylated peptide, is a competitive human renin inhibitor with the IC50 of 2.3 μM. U80215 shows excitation and emission maxima at 340 and 530 nm.
    U-80125
  • HY-177331
    BTT-3034 1259029-47-4
    BTT-3034, a sulfonamide derivative, is an α2β1 integrin inhibitor. BTT-3034 inhibits cell adhesion to rat tail collagen I with an EC50 of 160 nM and a corresponding Emaxof 86%. BTT-3034 inhibits collagen binding by an α2 variant carrying the conformationally activating E318W mutation.
    BTT-3034
  • HY-177361
    Zocainone 68876-74-4
    Zocainone is an antiarrhythmic agent. Zocainone blocks sodium channels in cardiac tissue, stabilizing the cardiac action potential and reducing abnormal electrical activity. Zocainone is promising for research of cardiac arrhythmias.
    Zocainone
  • HY-177433
    NLRP3 modulator 8 3069891-88-6 98%
    NLRP3 modulator 8 (Compound 14) is a NLRP3 modulator. NLRP3 modulator 8 significantly degrades NEK7 with an DC50 of 9  nM. NLRP3 modulator 8 dose-dependently inhibits caspase-1 activity and IL-1β release in macrophages in response to NLRP3 inflammasome activation. NLRP3 modulator 8 can be used for autoinflammatory and autoimmune disorders like multiple sclerosis, neurodegeneraive diseases like Alzheimer's disease and cardiovascular and melabolic disorders like pericarditis and Type 2 diabetes research.
    NLRP3 modulator 8
  • HY-177580
    GP1 precursor 1423134-36-4
    GP1 precursor has high affinity to GPIIb/IIIa receptors of activated platelets. GP1 precursor can be radiolabeled with [18F] and used as a PET Tracer for visualizing active platelet aggregation at the molecular level. GP1 precursor can be used for the detection of Thrombi.
    GP1 precursor
  • HY-178082
    MK-251 36386-71-7
    MK-251 is an orally active anti-arrhythmic agent. MK-251 prevents or modifies ventricular arrhythmias induced in dogs and baboons by tetrafluorethylbutylamine. MK-251 antagonizes the arrhythmias caused by Digoxin (HY-B1049) in cats. MK-251 at effective doses has little effect on basic cardiovascular parameters such as blood pressure, cardiac output, myocardial contractility and ventricular conduction, thus demonstrating its unique advantages.
    MK-251
  • HY-178139
    hMAO-B-IN-12 3087062-50-5
    hMAO-B-IN-12 (Compound 6E) is a highly selective human monoamine oxidase B (hMAO-B) inhibitor (IC50=17.7 nM). hMAO-B-IN-12 reduces oxidative stress/lipid metabolism-derived products (e.g., H2O2). hMAO-B-IN-12 is promising for research of atherosclerosis.
    hMAO-B-IN-12
Cat. No. Product Name / Synonyms Application Reactivity